A synthesis of cost-utility analysis literature in infectious disease.

Lancet Infect Dis 2005 Jun;5(6):383-91

Columbia University School of Nursing, New York, NY 10032, USA.

The purpose of this review is to understand infectious disease-related cost-utility analyses by describing published analyses, examining growth and quality trends over time, examining factors related to quality, and summarising standardised results. 122 cost-utility analyses and 352 cost-utility ratios were identified. Pharmaceutical interventions were most common (47.5%); three author groups accounted for 42.8% of pharmaceutical ratios. High-volume journals (three or more published cost-utility analyses) published higher quality analyses than low-volume journals (p<0.001). Use of probabilistic sensitivity analysis and discounting at 3% were more frequently found in the years after the US Public Health Service Panel on Cost-Effectiveness in Health and Medicine recommendations (p<0.01). Median ratios varied from US13,500 dollars/quality-adjusted life year (QALY) for immunisations to US810,000 dollars/QALY for blood safety. Publication of infectious disease cost-utility analyses is increasing. The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(05)70142-0DOI Listing
June 2005
3 Reads

Publication Analysis

Top Keywords

cost-utility analyses
12
analyses
5
identified pharmaceutical
4
ratios identified
4
pharmaceutical interventions
4
common 475%
4
cost-utility ratios
4
interventions common
4
352 cost-utility
4
factors quality
4
examining factors
4
time examining
4
quality summarising
4
standardised 122
4
analyses 352
4
122 cost-utility
4
475% three
4
three author
4
published higher
4
analyses published
4

Similar Publications